Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2016 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its third quarter 2016 financial results on Thursday, November 3, 2016, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, November 3, 2016, at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company’s financial results and provide a general business update.
The live audio webcast may be accessed through the “Events & Presentations” page in the “Investors” section of the company’s website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 3243563.
The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
Company Contact: Heather Rowe Investor Relations 415-365-5737 [email protected]
